Varex Schedules First Quarter Fiscal Year 2024 Earnings Release and Conference Call

SALT LAKE CITY–(BUSINESS WIRE)–Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2024 following the close of regular trading on Tuesday, February 6, 2024. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day.


This call will be webcast live and can be accessed at the company’s website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company’s website and a replay of the call will be available from February 6th through February 20th at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay conference call access code is 13743669. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=tUCJYtbr.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Contacts

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | [email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.